Pulmonary hypertension: reasonable selection of specific therapy

Pulmonary hypertension: reasonable selection of specific therapy

Pulmonary hypertension is characterized with persistent increase in pulmonary vascular resistance leading to progressive worsening of right ventricular failure and death. The basis for pulmonary arterial hypertension is structural changes in pulmonary arteries and arterioles caused by endothelial dy...

Full description

Bibliographic Details
Main Authors:	N A Karoli, S I Sazhnova, A P Rebrov
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2018-03-01
Series:	Системные гипертензии
Subjects:	pulmonary arterial hypertension endothelin receptor antagonists bosentan ambrisentan macitentan
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/29597/pdf

Similar Items

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
by: Correale M, et al.
Published: (2018-10-01)

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
by: Yusi Chen, et al.
Published: (2022-01-01)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
by: Yusi Chen, et al.
Published: (2022-04-01)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
by: Jie Li, et al.
Published: (2022-12-01)

Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
by: D Yu Platonov, et al.
Published: (2017-12-01)

Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01)

The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
by: S N Avdeev
Published: (2016-07-01)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
by: Monaco TJ, et al.
Published: (2016-05-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
by: S N Avdeev, et al.
Published: (2013-03-01)

A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension
by: O A Arkhipova, et al.
Published: (2016-12-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01)

Bosentan therapy for chronic thromboembolic pulmonary hypertension
by: L Huber, et al.
Published: (2007-10-01)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
by: Zeyu Zhang, et al.
Published: (2022-06-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
by: Ahmad Amin, et al.
Published: (2015-01-01)

Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension
by: O M Moisseeva, et al.
Published: (2017-03-01)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
by: Abdullah M. Aldalaan, et al.
Published: (2022-04-01)

Improvement in idiopathic interstitial pneumonia by adding macitentan to a patient unresponsive to nintedanib
by: Yosuke Tanaka, et al.
Published: (2024-01-01)

TACTICS FEATURES OF CONDUCTING AND CHOOSING SPECIFIC THERAPY FOR ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE
by: O. A. Arkhipova, et al.
Published: (2018-03-01)

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
by: Jiří Patočka, et al.
Published: (2005-01-01)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
by: Naomi Onda, et al.
Published: (2015-01-01)

AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Endothelin: setting the scene in PAH
by: J. Dupuis
Published: (2007-08-01)

UP-FRONT TRIPLE COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A CASE REPORT
by: A. V. Volkov, et al.
Published: (2018-03-01)

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial
by: Mandana Kashaki, et al.
Published: (2025-01-01)

Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats
by: A. Caires, et al.
Published: (2017-12-01)

CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis
by: Duygu Köse, et al.
Published: (2021-07-01)

Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
by: Jina Yeo, et al.
Published: (2022-04-01)

A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy
by: Tomoyuki Naito, et al.
Published: (2017-01-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
by: Karami H, et al.
Published: (2018-12-01)

Anti-inflammatory effects of endothelin receptor blockade in left atrial tissue of spontaneously hypertensive rats
by: A. Bukowska, et al.
Published: (2022-10-01)

The use of Macitentan in Fontan circulation: a case report
by: Polyvios Demetriades, et al.
Published: (2017-05-01)

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
by: M. Delcroix, et al.
Published: (2009-12-01)